InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Brentpdc Free
11/24/16 4:24 PM
profile icon
Brentpdc Free
11/12/16 3:40 AM
profile icon
Brentpdc Free
05/03/16 7:16 PM
profile icon
Brentpdc Free
01/07/15 2:40 PM
profile icon
Brentpdc Free
01/03/15 10:19 PM
profile icon
Brentpdc Free
12/29/14 12:11 PM
profile icon
Brentpdc Free
12/23/14 1:48 PM
profile icon
Brentpdc Free
12/19/14 1:48 PM
profile icon
Brentpdc Free
12/18/14 11:46 AM
profile icon
Brentpdc Free
12/17/14 1:16 PM
profile icon
Brentpdc Free
12/13/14 5:25 PM
profile icon
Brentpdc Free
12/08/14 2:06 PM
profile icon
postyle Grandfathered
12/08/14 1:53 PM
profile icon
Brentpdc Free
12/08/14 1:48 PM
profile icon
postyle Grandfathered
12/08/14 1:47 PM
profile icon
Brentpdc Free
12/08/14 12:58 PM
profile icon
postyle Grandfathered
12/08/14 12:57 PM
profile icon
Brentpdc Free
12/08/14 11:26 AM
profile icon
Brentpdc Free
12/06/14 2:32 AM
profile icon
Brentpdc Free
04/05/14 12:51 AM
profile icon
johan31 Free
12/14/12 1:11 PM
profile icon
johan31 Free
12/14/12 12:47 PM
profile icon
Harleyman Free
12/14/12 12:13 PM
profile icon
rarefind Free
12/14/12 11:42 AM
profile icon
Barney Vissur Terminated
12/14/12 11:12 AM
profile icon
Harleyman Free
12/14/12 10:13 AM
profile icon
Barney Vissur Terminated
12/14/12 9:53 AM
profile icon
Barney Vissur Terminated
12/14/12 9:39 AM
profile icon
rarefind Free
12/14/12 8:40 AM
profile icon
Harleyman Free
12/14/12 8:04 AM
profile icon
Barney Vissur Terminated
12/14/12 7:50 AM
profile icon
otterman Free
12/12/12 1:07 PM
profile icon
rarefind Free
12/12/12 12:01 PM
profile icon
Jamming1 Terminated
12/12/12 11:01 AM
profile icon
Harleyman Free
12/12/12 11:01 AM
profile icon
Roo5guy Free
12/12/12 10:40 AM
profile icon
Harleyman Free
12/12/12 10:34 AM
profile icon
postyle Grandfathered
12/12/12 10:22 AM
profile icon
tooshreddedforyou Free
12/12/12 10:14 AM
profile icon
Harleyman Free
12/12/12 10:04 AM
profile icon
surf1944 Free
12/12/12 9:37 AM
profile icon
porgyrusty Free
12/12/12 9:35 AM
profile icon
postyle Grandfathered
12/12/12 9:29 AM
profile icon
enchanted Free
12/12/12 9:26 AM
profile icon
Harleyman Free
12/12/12 8:35 AM
profile icon
Harleyman Free
12/11/12 9:57 PM
profile icon
surf1944 Free
12/10/12 9:35 AM

YM BioSciences Inc. (YMI) RSS Feed

Followers
28
Posters
128
Posts (Today)
0
Posts (Total)
923
Created
07/17/05
Type
Free
Moderators

YMI BioSciences, Inc.

Company Background
GYM BioSciences Inc. (YM) is a biopharmaceutical company engaged in the development of products for the treatment of patients with cancer. The Company owns or in-licenses substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. It conducts and out-sources clinical trials and it out-sources the manufacture of clinical materials to third parties. Its portfolio of products in active clinical development includes three anti-cancer agents in numerous clinical trials. Its small molecule Janus Kinase (JAK) 1/2 inhibitor, CYT387, is in clinical development for myeloproliferative neoplasm-tumors (MPNs) and may have applications in solid tumors, as well as inflammatory disease. Its monoclonal antibody, nimotuzumab, is being developed in 11 clinical trials by YM and its licensees in numerous solid tumor indications. On March 9, 2010, Cytopia Limited changed its name to YM BioSciences Australia Pty Ltd.
 

CYT997 has completed two Phase I studies in advanced solid tumors and is currently being studied in a Phase II clinical trial in combination with chemotherapy in patients with relapsed glioblastoma multiforme. Results from the intravenous Phase I dose escalation study were published in the British Journal of Cancer (Lickliter et al, 2010), and demonstrated clinically meaningful disease stabilization in the majority of patients treated. Data showed that CYT997 administration was associated with changes in plasma and imaging biomarkers consistent with vascular disruption in tumors. Magnetic resonance imaging showed significant changes in tumor perfusion consistent with vascular disruption in some patients. Data from the Phase I oral study of CYT997 in patients with advanced cancer were reported at ASCO 2009 (Francesconi et al, 2009).

 

 

2011 2nd Quarter http://www.ymbiosciences.com/upload_files/YM_Q2_2011.pdf 
2011 3rd Quarter http://www.otcmarkets.com/stock/YMI/news
 
 

2010 Annual Report 10-K http://www.ymbiosciences.com/upload_files/YM_AR_2010.pdf

 

 


Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
YMI Latest News
  • No Recent News Available for this company!
New Post